Gaia, the fertility payment solution that allows patients to pay only when treatment is successful, has announced a partnership with Genomic Prediction’s LifeView, a provider of advanced embryo screening technology. The collaboration aims to address both financial and medical barriers to IVF treatment.
Gaia offers personalized financial plans that spread costs over time and only require payment if patients bring home a baby. This approach reduces the financial uncertainty that often prevents people from pursuing fertility treatments. Through the new partnership, Gaia Members will now have access to LifeView’s embryo screening technology, which can improve IVF outcomes by assessing embryos for genetic health and reducing miscarriage risk.
“At Gaia, we believe that access to fertility treatment shouldn’t be dictated by financial uncertainty,” said Nader AlSalim, Founder & CEO of Gaia. “By partnering with LifeView, we’re not only helping patients afford IVF but also improving their chances of success with cutting-edge embryo screening. This collaboration means more people can pursue treatment knowing they have both a financial safety net and the best possible chance of bringing home a baby.”
LifeView’s technology includes several testing options that will be available to Gaia Members. The Embryo Health Score Test (EHS) provides insight into the likelihood of developing conditions influenced by multiple genes, including cardiovascular disease, diabetes, certain cancers, and mental health conditions.
Additionally, LifeView offers PGT-A, which identifies chromosome abnormalities in embryos; PGT-A+, which determines whether abnormalities originate from the mother, father, or embryo; PGT-M, which reduces the chance of passing on single-gene conditions; and PGT-SR, which detects chromosome abnormalities and structural imbalances.
“Genomic Prediction shares Gaia’s commitment to prioritizing education, research, and the needs of patients, ensuring they have the best opportunities to achieve their family-building goals,” said Kelly Ketterson, CEO of Genomic Predictions. “We are honored to partner with Gaia, an organization that understands the importance of patients’ perceptions of value as a fundamental aspect of an effective fertility treatment plan.”
